GConferenceGridThe Conference Catalogue · Vol. 2027Folio № C6BBA7
Finance & Banking

BIO Investment & Growth Summit 2026

T

he new biotech CEO and investor conference from BIO, the BIO Investment & Growth Summit.

Visit the official site
44Voices
13Underwriters
0Exhibitors
29On the bill · sessions
54Companies · in total
§I

The Voices

Programmed at BIO, in alphabetical order.
Abhijit Bhatia
Chief Operating Officer · Rakuten Medical
Amir Hefni
CEO · Resolution Therapeutics
Andrew Hall
CEO · Consano Bio
Andy Lee
Co-founder & CBO · Vincere Biosciences Inc
Anna Abram
Senior Advisor, Health Care Policy and Legislation · Akin
Atul Deshpande
Chief Executive Officer · IMMEDIATE TX
Bernard Cooney
Senior Partner, Capital Formation · Flagship Pioneering
Chris Dokomajilar
Founder and CEO · DealForma
Christer Rosén
Chairman & CEO · Jupiter Neurosciences, Inc.
Courtney Miller
Co-Founder, Myosin Therapeutics; Professor, Department of Molecular Medicine, Department of Neuroscience · UF Scripps Biomedical Research
Daniel Brog
Managing Director · Locust Walk
Daniel Haders
CEO · Model Medicines
Dan Salain
President & CEO · Recall Therapeutics
Douglas Dieter
Partner, Portfolio Manager and Co-Head of Ares Specialty Healthcare · Ares Credit Group
Ed Arce
Managing Director, Senior Biotechnology Analyst · WestPark Capital
Edward Chow
CSO · KYAN Technologies
Frank Ahmann
President & CEO · XM Therapeutics, Inc.
Frederic Cadet
Founder & Board Chair · PEACCEL
Greta Garrido
CEO & Co-Founder · Sebastian Biopharma, Inc.
Gunner Hardy
Senior Associate · BOLD Longevity Growth Fund
Jayson Slotnik
Principal · Health Policy Strategies
Jeffrey Cleland
Chairman, CEO & President · Programmable Medicine

— and 22 more, by name unsung —

§II

Underwritten By

The houses behind the program. Tiers as disclosed.
AvantorPremier
BIOPartner
Blaise Group InternationalConference
CHUBBConference
Corporate TravelerConference
CytovancePremier
freemindPartner
GATCConference
Johnson & Johnson Development CorporationPremier
ScendeaConference
Southern Star ResearchConference
Syneos HealthPremier
The Money Channel NYCConference
§III

The Programme

Selected from 29 sessions on the bill.
  • 01:30 PM 02:15 PM

    Session: The High-Impact Investment Landscape in Immunology & Inflammation

  • 01:30 PM – 02:15 PM

    The High-Impact Investment Landscape in Immunology & Inflammation

    Expansion in the target landscape, from TL1A and beyond, has accelerated progress in I&I drug development with multibillion-dollar M&A across the past two years attracting more fun…

  • 01:30 PM – 02:30 PM

    Spotlight on Innovation

    The Innovation Stage offers a mix of programming showcasing biotech companies seeking breakthrough treatments and the University of Florida.

  • 02:00 PM – 02:30 PM

    Gator Dynamism: University of Florida’s Innovation in Biotech

  • 02:30 PM 03:15 PM

    Session: Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines

  • 02:30 PM – 03:15 PM

    Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines

    GLP-1 analogs have rewritten treatment standards and changed patients’ expectations related to obesity, yet even more tantalizing is growing evidence they could hold the key to bro…

  • 02:45 PM 03:30 PM

    Session: Derisking Commercialization Plans to Attract Investment

  • 02:45 PM – 03:30 PM

    Derisking Commercialization Plans to Attract Investment

    As biotech funding dynamics evolve, investors are seeking capital models that reward commercial discipline and strategic partnership. Traditional venture pathways are giving way to…

  • 03:45 PM 04:30 PM

    Session: Balancing Global Opportunities and Trade Policy Risks

Intermission
Part the Second · For the Buyer

An audience of 54 companies, parsed from the program.

54 companies in attendance.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

01Fig. 01 — Composition of the House
0All threespeak · spons · exh
13Sponsoringsponsor only
0Exhibitingexhibitor only
41Speakingspeaker only
02Fig. 02 — The Voices, by Seniority

86% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

  • C-suite2557%
  • Founder / Owner716%
  • VP-level12%
  • Director / Head of511%
  • Manager / Lead12%
  • Advisor / Investor12%
  • Other roles49%

Of 44 on the bill · classified by free-text title

03Fig. 03 — The Heaviest in the Room
  1. 01AvantorSp·P
  2. 02BIOSp·P
  3. 03Blaise Group InternationalSp·C
  4. 04ChubbSp·C
  5. 05Corporate TravelerSp·C
  6. 06CytovanceSp·P
  7. 07freemindSp·P
  8. 08GATCSp·C
  9. 09Johnson & Johnson Development CorporationSp·P
  10. 10ScendeaSp·C
  11. 11Southern Star ResearchSp·C
  12. 12Syneos HealthSp·P
  13. 13The Money Channel NYCSp·C
  14. 14Akin1V
04Fig. 04 — By Tier
conference7
54% of 13
partner2
15% of 13
premier4
31% of 13
06Fig. 06 — Adjacent Convocations · by shared underwriters